Novo Nordisk A/S - The Final Phase 3a Trial for IDegLira Completed,
and FIAsp Approved for Phase 3 Development
BAGSVAERD, DENMARK -- (Marketwire) -- 12/19/12 -- Company
Announcement No 83 2012: http://hugin.info/2013/R/1666389/540820.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novo Nordisk A/S via Thomson Reuters ONE
Novo Nordisk A/S
Novo Alle , DK-2880
*T. Tlf. +45 44 44 88 88
*F. Fax +45 44 44 49 05
Press spacebar to pause and continue. Press esc to stop.